Background and aims: Data on the efficacy and safety of seasonal influenza vaccines in patients with inflammatory bowel disease (IBD) remain scarce. The aim of the study was to evaluate the impact of immunosuppressive (IS) therapeutics on serological response to 2-year influenza vaccination in IBD adults. Methods: A multicentre prospective study performed in 255 IBD adults (18-64 years) receiving the trivalent influenza vaccine in the years 2009-2010 and 2010-2011. Haemagglutination inhibition (HI) titres were assessed before and 3 weeks and 6 months after vaccination. Results: At inclusion, 31 patients were receiving no IS treatment (Group A), 77 were receiving IS treatment without anti-TNF (Group B) and 117 were receiving anti-tumour necrosis factor (TNF) treatment with or without IS treatment (Group C). Three weeks after the first vaccination, rates of seroprotection were 77, 75 and 66% for strain A/H1N12007 (p = 0.35), 77, 68 and 52% for strain A/H3N2 (p = 0.014) and 97, 96 and 95% for strain B (p = 0.99) in Groups A, B and C, respectively. Seroconversion rates for A/H1N12007 (67, 64 and 54%; p = 0.28), A/H3N2 (63, 50 and 41%; p = 0.074) and strain B (63, 76 and 60%; p = 0.078) were not significantly different among treatment groups. At 6 months after vaccination, seroprotection rates were lower in Group C compared with Groups A and B. Comparable results were observed for the second year of vaccination. No impact on Harvey-Bradshaw and Mayo scores was detected. Conclusions: Influenza vaccine yielded high seroprotection rates in IBD patients. Persistence of seroprotection was lower in patients with anti-TNF treatment.
Introduction
Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine, including Crohn's disease and ulcerative colitis. Mucosal inflammation of the bowel is thought to be the consequence of environmental factors, infectious organisms, genetic susceptibility and a dysregulated immune system. 1 Patients with IBD receive long-term immunosuppressants such as corticosteroids, methotrexate, thiopurines and tumour necrosis factor (TNF) inhibitors. 2 The possible consequence of these drugs is increased susceptibility to infections and several studies showed that TNF inhibitors lead to an increased risk of opportunistic infections, serious infections and hospitalizations. [3] [4] [5] [6] Patients with IBD are at risk of vaccine-preventable illnesses such as influenza. 7 National and international guidelines recommend vaccinating patients with immunocompromised conditions against influenza infection each year. [8] [9] [10] [11] [12] Despite these recommendations, the vaccination coverage of seasonal influenza remains insufficient, with fewer than one immunocompromised patient out of three being immunized.' 13, 14 Concerns about safety and poor immunogenicity have been reported as possible causes of low vaccination coverage in immunocompromised patients. 13, 15 In children with IBD, Mamula et al. 16 showed that patients on combined anti-TNF and immunomodulatory therapy were at risk of inadequate response to vaccination against seasonal influenza; the vaccination was nevertheless safe and IBD was not exacerbated. In adults with IBD, two studies were conducted to evaluate the immunogenicity of the pandemic 2009 A/ H1N1 influenza vaccine, with or without adjuvant, and showed that patients receiving combined anti-TNF and immunomodulatory therapy had the lowest rates of serological response to the vaccines. 17, 18 Similar findings were reported for the seasonal trivalent influenza vaccine in the study conducted by Hagihara et al., 19 showing that treatment with infliximab and/or immunomodulatory therapy reduced the immune response to vaccination. However, different results have been reported in other clinical situations. In a study conducted in patients with autoimmune disease and a control group of healthy individuals, the antibody response to influenza vaccination was only slightly impaired in patients treated with anti-TNF. 20 The proportion of patients who achieved a protective titre was not significantly decreased by anti-TNF therapy. In another study in rheumatoid patients, a good humoral response was obtained after influenza vaccination, although the response was lower than in healthy controls. The efficacy was not affected by immunosuppressive (IS) treatments, particularly anti-TNF therapy. [21] [22] However, specific data on the efficacy and safety of seasonal influenza vaccines in IBD patients remain scarce. Lack of consistency is found in studies conducted in IBD adults, including studies with small sample sizes. Besides, none of these studies assessed the kinetics of immune response over 1 year and the impact of revaccination, two very important points for patients for whom vaccination should be done every year.
The aim of this prospective study was to assess in two successive years the immunological efficacy and safety of influenza vaccination in a large number of adults with IBD, comparing patients receiving IS treatments (including or not including anti-TNF) with patients not receiving IS therapeutics.
Materials and methods

Study design
The MICIVAX trial was a Phase 3, open-label, multicentre prospective clinical trial performed in 16 centres in France. The study was scheduled to run in two successive years.
Patients with Crohn's disease or ulcerative colitis were eligible to participate if they were aged 18-64 years, had received at least 3 months of treatment for patients treated with an immunosuppressant or anti-TNF, or had no indication to start treatment with IS therapeutics in the following 3 months. Patients were excluded according to the following criteria: receiving treatment with corticoids alone without immunosuppressant or anti-TNF; having fever or acute infection the week prior to vaccination; having allergy to any component of the vaccine; receiving seasonal influenza vaccine within the last 6 months; having a history of progressive neuropathy or Guillain-Barré syndrome; having HIV, HBV (positive for hepatitis B surface antigen) or hepatitis C virus infection; having other causes of immune deficiency; receiving cellular therapy, immunoglobulin infusion, treatment with blood-derived products or monoclonal antibodies other than anti-TNF within the last 3 months. Women with positive urinary β-human chorionic gonadotropin (tested before each vaccination) were excluded.
Blood samples were planned for assessment of haemagglutination inhibition (HI) antibodies against vaccine antigens prior to vaccination, at any day between Day 21 and Day 28 and Month 6 for both Year 1 and Year 2 after each vaccination. Patients were categorized according to IBD treatment during the 3 months preceding vaccination: patients who did not receive any IS therapeutics, including patients treated with 5-aminosalicylates and/or antibiotics (Group A), patients who received IS without anti-TNF treatment (Group B) and patients who received anti-TNF treatment with or without IS (Group C).
Written informed consent was obtained from each patient. The protocol was conducted in accordance with the Declaration of Helsinki and French law for biomedical research and was approved by the 'Ile-de France 3' Ethics Committee (Paris, France), on September 8, 2009 . The study was registered with ClinicalTrials.gov, with the identifier NCT01022749.
Clinical activity scores (Harvey-Bradshaw score for Crohn disease and Mayo score for ulcerative colitis) were recorded for each subject. Medical records were reviewed for information on IBD diagnosis, duration of disease, current and past treatment and significant medical history.
Vaccines
The anti-influenza vaccine used (Vaxigrip ® ; Sanofi Pasteur MSD) was a trivalent inactivated split-virion vaccine supplied in prefilled 0.5-mL syringes containing influenza virus from three strains ( products/biological_reference_materials/product_catalogue/sub_cat-egory_listing.aspx?category=Vaccines&subcategory=Influenza) on human O Rh-red blood cells. The titre of haemagglutination-inhibiting antibodies against a single antigen was defined as the reciprocal of the highest serum dilution that completely inhibited red blood cell agglutination induced by this antigen. All sera of an individual patient were analysed on the same microtitre plate. Sera whose titres were <10 were assigned a titre of 5 for calculation purposes.
Assessments of immune response
Safety/reactogenicity assessments
Diary cards were provided to record the occurrence and intensity of injection-site-solicited adverse events (ecchymosis, pain, redness and swelling) and systemic-solicited adverse events (generalized/ widespread arthralgia, fatigue, gastrointestinal symptoms, headache, generalized/widespread myalgia, shivering and fever) experienced during the first 5 days after vaccination. In addition, data were collected on the occurrence and intensity of any unsolicited adverse events that occurred within 21 days after vaccination (all solicited and unsolicited data were reviewed at a Day 21 visit) and all adverse events with a medically attended visit up to 180 days after vaccination (these events were reviewed by visit on Day 180).
To measure intensity, the diameters of any injection site ecchymosis, redness and swelling were measured (Grade 3 was defined as diameter >100 mm) and daily body temperature was recorded. Intensities of other adverse events were recorded according to a standard three-grade scale: 'easily tolerated' ('painful on touch' for injection site pain); 'interfered with normal activity' (or 'painful when limb was moved' for injection site pain); and 'prevented normal activity' (or 'considerable pain at rest' for injection site pain).
Harvey-Bradshaw and Mayo scores were recorded for each subject at each visit.
Data on serious adverse events (SAEs), IBD flares and adverse events of specific interest (in particular autoimmune diseases such as neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, autoimmune blood disorders, inflammatory skin disorders and other autoimmune/inflammatory events) were collected during the whole of the year following vaccination.
An assessment of causality was made by the investigator for solicited systemic and unsolicited adverse events, as well as for SAEs, IBD flares and adverse events of specific interest. Solicited local adverse events were always considered to be related to vaccination. An independent data monitoring committee consisting of an internist and an infectious diseases specialist reviewed all SAEs, adverse events of ( Grades 3 and 4 and all IBD flares occurring during the 3 months after vaccination, and the causality was discussed with the investigator. Subjects having an influenza-like illness, defined as an oral temperature higher than 37.8°C with at least one influenza-like symptom (cough, sore throat, rhinorrhoea, nasal obstruction) were asked to provide specimens of nasal and throat swabs for virological testing.
Statistical analysis
We initially planned to recruit 100 patients in each group to show the superiority in immune response rate in Group A (70%) compared with Group B or C (48% each, power 80%, α risk 0.025). However, enrolment of Group A patients was lower than expected, possibly due to the pandemic context, and post hoc statistical analyses were performed.
We adopted a closed testing procedure, i.e. a comparison at the 0.05 level of immune response between all three groups and, in cases of significance, additional pairwise comparisons with a p-value of 0.017 indicating significance.
The primary endpoint was the seroconversion rate, defined as the percentage of patients with a post-vaccination titre ≥1:40 and at least a 4-fold increase between post-vaccination (3 weeks after vaccination) and pre-vaccination titres. Secondary endpoints were: seroprotection rate, defined as the percentage of patients with a post-vaccination HI titre ≥1:40 achieved 3 weeks after influenza vaccination for each virus strain; and the fold rise in geometric mean titre (GMT) (geometric mean of the within-subject ratios of postvaccination reciprocal HI titre with respect to the Day 0 reciprocal HI titre). 24 For data processing, titres less than 1:10 were regarded as 1:5 and reciprocal antibody titres were analysed after logarithmic transformation. The results were presented on the original scale by calculating the antilogarithm.
Qualitative variables were compared across groups using Fisher's exact test and quantitative variables using the Mann-Whitney test. A linear mixed model with unstructured correlation was used for comparisons of repeated measures (GMT, Harvey-Bradshaw and Mayo scores). This statistical model took within-subject correlation into account. Pairwise comparisons between groups were performed using the F test statistic, with a p-value of 0.017 indicating significance. Logistic regression with backward selection was used to analyse the independent predictive factors associated with seroprotection (HI titre ≥1:40).
Influenza-like episodes according to the Centres for Diseases Control and Prevention definition (fever >37.8°C plus sore throat or cough) were recorded in patient diary; influenza-like symptoms related to vaccination were excluded.
All statistical computations were performed using SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA). 
Results
Study patients
From September 28 to December 9, 2009, 225 patients with IBD aged from 18 to 64 years were included in the study. Thirty-one were receiving no IS treatment (Group A), 77 were receiving IS treatment without anti-TNF (Group B) and 117 were receiving anti-TNF treatment with or without IS (Group C). One hundred and sixty-three patients received a second vaccination, 33 were receiving no IS treatment, 49 were receiving IS treatment without anti-TNF and 81 were receiving anti-TNF treatment. A flow chart for vaccinations at Year 1 (2009 Year 1 ( -2010 and Year 2 (2010 Year 2 ( -2011 ) is presented in Figure 1 . The demographic profiles and clinical characteristics of the three groups according to IS treatment at Year 1 are described in Table 1 and Supplementary data, Table 1 . Baseline characteristics were comparable except for the proportion of patients with Crohn's disease (higher in Groups B and C compared with Group A) and for mean Harvey-Bradshaw score, which was significantly higher in Group C and lower in Group B compared with Group A.
Fifty-two patients received one or two intramuscular injections of pandemic 2009 A/H1N1v vaccine: 35 an adjuvanted vaccine (Pandemrix™; GSK Bio), 14 received a non-adjuvanted vaccine (Panenza™, Sanofi-Pasteur) and 3 received an unknown vaccine.
Immunogenicity
At enrolment (baseline of Year 1), rates of seroprotection (HI titre ≥1:40) in Groups A, B and C were low for strains A/H1N12007 (10, 12 and 9%) and A/H3N2 (16, 18 and 9%) and high for strain B (35, 49 and 40%) ( Table 2 ); no significant difference according to treatment group was evidenced.
Three weeks after the first vaccination, rates of seroprotection assessed in groups A, B and C were 77, 75 and 66%, respectively, for strain A/H1N12007 (p = 0.35), 77, 68 and 52% for strain A/H3N2 (p = 0.014) and 97, 96 and 95% for strain B (p = 0.99). Seroconversion rates for strain A/H1N12007 (67, 64 and 54% in groups A, B and C, respectively; p = 0.26), strain A/H3N2 (63, 50 and 41%; p = 0.074) and strain B (63, 76 and 60%; p = 0.078) were not significantly different according to treatment group. Fold increases in GMT for strain A/H1N12007 (7.9, 7.7 and 6.8 in groups A, B and C, respectively; p = 0.82), strain A/H3N2 (6.5, 4.1 and 3.2; p = 0.0348) and strain B (7.0, 6.5 and 5.0; p = 0.21) indicated a significantly higher increase for strain A/H3N2 in Group A compared with Group C.
Durability of seroprotection was different according to treatment groups. At 6 and 12 months after vaccination, HI titres ≥1:40 were less frequent in Group C compared with Groups A and B for strains A/H1N12007 and A/H3N2 (Table 2) .
Results for seroprotection, seroconversion and fold increase in GMT for Year 2 were comparable to the results for Year 1 (Table 3) .
Overall, values of GMT following the first vaccination in Group C were lower compared with the other treatment groups for the 2 years (Figures 2 and 3 ) This difference in GMT values according to treatment group was less marked for strain A/H1N1v2009 in the subgroup of patients who also received this monovalent vaccination (Figure 3) .
Logistic regression analyses were performed to determine the independent predictive factors for seroprotection (HI ≥1:40) after vaccination (Table 4) the persistence of seroprotection at 6 months after vaccination (in strain A/H3N2 in Years 1 and 2; in A/H1N12007 in Year 1; in A/ H1N1v2009 Year 2). An impaired immune response among anti-TNF treated patients was observed not only when anti-TNF was combined with immunosuppressants but also when it was administered alone (Supplementary data, Table 2 ).
Safety
At least one adverse event was reported during the 2-year follow-up in 81% (25/31), 81% (62/77) and 85% (99/117) of patients in Groups A, B and C, respectively (p = 0.7322). At least one vaccine-related event was reported in 10% (3/31), 19% (15/77) and 12% (14/117) of patients. The vaccine-related adverse events were mainly of Grade 1 (6% of patients; 14/225) or Grade 2 (6% of patients; 14/225). The most frequent vaccine-related events (>1% of patients) were asthenia (11/225; 5%), myalgia (6/225; 3%), pyrexia (4/225; 2%), vaccinationsite erythema (6/225; 3%) and vaccination-site pain (5/225; 2%). No difference in vaccine reactions was found between treatment groups except that local pain was more frequent in Group B (52%) than in Groups A and C (22 and 32%, respectively) ( Table 5) . Changes in Harvey-Bradshaw and Mayo scores during the 2 years of the study are described in Figure 4 . Harvey-Bradshaw scores were overall lower in Group B than in the two other groups (p = 0.0169), but did not exhibit any significant variations following vaccination (p = 0.5775). Mayo scores did not differ significantly between groups (p = 0.6999) but decreased overall with time (p = 0.0127)
A total of 126 systemic adverse events were reviewed by the independent data monitoring committee: 76 were judged to be not attributable to the vaccine. The remaining 50 adverse events were resubmitted to investigators' centres to provide clarification on the status of IBD at baseline and confirm whether they were attributable to the vaccine. Eventually, 10 adverse events were reported to be vaccine-related, probably related or 'unknown'. These 10 adverse events concerned 6 patients: 2 of the 10 patients had a relapse of Crohn's disease, 1 had rectal syndrome (rectal bleeding, urgency of defaecation), 1 had psoriasiform eruption, 1 had abdominal pain, 1 had asthenia, 1 had nausea, 1 had aching muscles, 1 had fever and 1 had diarrhoea. The 2 patients with Crohn's disease exacerbation were in the group treated with anti-TNF.
The percentages of patients without influenza-like episodes during the first season were 93, 80 and 83 in Groups A, B and C, respectively (p = 0.3970); corresponding percentages in the second season were 85, 84 and 78 (p = 0.8889). Twenty-five nasal swabs were available for 22 patients: 10 during the first year and 15 during the second year.
Four patients tested positive for 2009 A(H1N1) influenza during the second year, 57, 75, 87 and 108 days after vaccination, and one tested positive for B influenza 119 days after vaccination.
Discussion
Our study is the first clinical prospective study designed to evaluate the immunogenicity and safety of two successive years of seasonal influenza vaccination in a large population of adult patients with IBD. We observed that the seasonal influenza vaccines recommended in 2009-2010 and 2010-2011 conferred a high immune response in a population of IBD patients aged 18-64 years. According to the criteria defined by the European Union Committee for Medicinal Products for Human Use (CHMP) for the assessment of seasonal influenza vaccines in immunocompetent adults aged 18-60 years, at least one of the following serological criteria for HI antibody response should be achieved: seroprotection >70%, seroconversion >40% or geometric mean fold rise > 2.5. Although at least one of these criteria was achieved for the three influenza strains (A/H1N1, A/H3N2, B) for the two successive seasons, we observed that HI antibody response against A/H3N2 and A/H1N1 strains was lower and declined more rapidly in the group of patients receiving anti-TNF. Seroprotection rates against the B strain increased after vaccination, with high baseline rates for all treatment groups, including patients treated with anti-TNF. Influenza B mutates more slowly than influenza A strains and, due to a lack of antigenic diversity, immunity to influenza B is frequently achieved at an early age. Previous studies in children with IBD showed that vaccination against seasonal influenza was satisfactory. Variations in rates of seroprotected children among some flu vaccine strains have been reported, however, particularly in patients receiving immunomodulatory treatments. 16, [25] [26] [27] In adults with IBD, Cullen et al. 18 reported a low rate of seroprotection after A/H1N1 2009 influenza vaccination, particularly in patients with IS drugs. The lowest rates were observed in patients with combined immunosuppression (36 versus 64% in IBD patients without immunosuppression; p = 0.02). Comparable suboptimal responses to influenza A/H1N1 2009 vaccine were recently reported by Andrisani et al. 17 in IBD patients with combined therapy with immunosuppressants. By contrast, the immune response to influenza vaccine was not reduced by anti-TNF in a meta-analysis assessing the effect of rheumatoid arthritis treatments on the response to immunization. 28 Patients with systemic inflammatory disease and/or auto-immune disease, particularly when they receive IS drugs, have an increased risk of serious infections. 29, 30 Annual influenza vaccination is recommended for adults taking IS drugs. 10, 31 Despite these guidelines, the rate of vaccination in IBD patients remains low. In our study, only 19-25% of the patients were vaccinated against influenza within past 3 years. Comparable results were reported in the study of Lanternier et al., 3 with only 28% of adult patients receiving IS therapy for systemic inflammatory disease were vaccinated; in the study of Melmed et al., 7 28% of patients with IBD reported receiving routine influenza vaccination. These low vaccination rates appear to be mainly related to the absence of recommendations from the physician and fear of side effects. 13 Indeed, there have been concerns about possible flares in patients with systemic inflammatory and/or autoimmune diseases after influenza vaccination because these patients frequently receive IS drugs. 8 In the study of Rahier et al., 32 which was designed to assess the safety of vaccination against pandemic A/H1N1 2009 virus in 575 IBD patients, absence of flare was evidenced for 96.7% of patients with Crohn's disease and 95.6% with ulcerative colitis. In our study, disease exacerbation related to vaccine according to the investigator was reported in two patients out of 92 with Crohn's disease receiving anti-TNF. In the patients with Crohn's disease, Harvey-Bradshaw scores remained stable in the three treatment groups.
There are several limitations to our study. First, the treatment groups were not randomized and it could be argued that the observed differences in immunization could be, at least in part, related to disease severity and not to anti-TNF treatment. Nevertheless, the multivariate analysis suggests that anti-TNF treatment is an independent predictive factor for a low seroprotection rate. Second, the present study was not designed to assess the incidence of proven influenza infection in the vaccinated population, which is the preferred clinical endpoint for efficacy of influenza vaccination. Due to the low incidence of influenza-like illnesses, the seroprotection rate is considered to be an acceptable surrogate endpoint, not only in healthy controls but also in the immunocompromised population. 33 In conclusion, in adult patients with IBD, the trivalent influenza vaccines yielded high seroprotection rates, but with lower seroprotection against H3N2 and H1N1 strains than against strain B and more rapid decline in patients receiving anti-TNF with or without IS treatment. These results support the recommendations for vaccination of patients with IBD, but more immunogenic vaccines for patients receiving anti-TNF are needed.
